Cargando…

Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study

AIMS: A number of intervention studies have shown that therapy with angiotensin receptor blockers, such as irbesartan, can improve metabolic parameters and reduce the incidence of diabetes mellitus. It is unknown whether this observation also holds true in routine clinical settings. METHODS: We eval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parhofer, Klaus G, Münzel, Felix, Krekler, Michael
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211461/ https://www.ncbi.nlm.nih.gov/pubmed/18042288 http://dx.doi.org/10.1186/1475-2840-6-36

Ejemplares similares

Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide
por: Flack, J M
Publicado: (2007)

Comparative effect of angiotensin II type I receptor blockers and calcium channel blockers on laboratory parameters in hypertensive patients with type 2 diabetes
por: Nishida, Yayoi, et al.
Publicado: (2012)

Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients
por: Kintscher, Ulrich, et al.
Publicado: (2007)

Effects of Ang II Receptor Blocker Irbesartan on Adipose Tissue Function in Mice with Metabolic Disorders
por: Maeda, Akinobu, et al.
Publicado: (2014)

Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide
por: Mamdani, Muhammad, et al.
Publicado: (2019)

Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke
por: Kikuchi, Kiyoshi, et al.
Publicado: (2013)

Irbesartan, an angiotensin II type 1 receptor blocker, inhibits colitis-associated tumourigenesis by blocking the MCP-1/CCR2 pathway
por: Hachiya, Kensuke, et al.
Publicado: (2021)

Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer
por: Jones, M. R., et al.
Publicado: (2016)

Angiotensin II Receptor Blocker Irbesartan Enhanced SIRT1 longevity Signaling Replaces the Mitochondrial Biogenetic Survival Pathway to Attenuate Hypertension-Induced Heart Apoptosis
por: Pai, Pei-Ying, et al.
Publicado: (2022)

To do or not to do: Angiotensin converting enzyme inhibitors/angiotensin receptor blocker in COVID-19 elderly patients
por: Vura, Naga Venkata Rama Krishna, et al.
Publicado: (2021)

Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study
por: Chang, Chia-Hsuin, et al.
Publicado: (2014)

Implications of renin‐angiotensin‐system blocker discontinuation in acute decompensated heart failure with systolic dysfunction
por: Darden, Douglas, et al.
Publicado: (2019)

Interleukin-6 predicts inflammation-induced increase of Glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism
por: Lebherz, Corinna, et al.
Publicado: (2016)

Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study
por: Nishida, Yayoi, et al.
Publicado: (2013)

Irbesartan in experimental diabetic nephropathy
por: Mahajan, Rajiv, et al.
Publicado: (2010)

Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study)
por: Peters, Christian Daugaard, et al.
Publicado: (2015)

Protective Effects of Irbesartan, an Angiotensin Receptor Blocker with PPARγ Agonistic Activity, against Estradiol Benzoate-Induced Endometrial Hyperplasia and Atypia in Female Rats via Modulation of TNFα/Survivin Pathway
por: Morsy, Mohamed A., et al.
Publicado: (2021)

Irbesartan inhibits metastasis by interrupting the adherence of tumor cell to endothelial cell induced by angiotensin II in hepatocellular carcinoma
por: Feng, Long-Hai, et al.
Publicado: (2021)

Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records
por: Kitamura, Noboru, et al.
Publicado: (2007)

The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat
por: Habibi, Javad, et al.
Publicado: (2019)

Metabolic syndrome predicts vascular changes in whole body magnetic resonance imaging in patients with long standing diabetes mellitus
por: Findeisen, Hannes M, et al.
Publicado: (2010)

Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice
por: Zhang, Zhen-Zhou, et al.
Publicado: (2013)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study
por: Williams, Bryan, et al.
Publicado: (2014)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry
por: Bramlage, Peter, et al.
Publicado: (2015)

Action of irbesartan on blood pressure and glucose/lipid metabolism, in hemodialysis patients with hypertension
por: Onishi, Akira, et al.
Publicado: (2013)

A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan
por: Wu, Lung-Sheng, et al.
Publicado: (2016)

Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT)
por: Cohen, Jordana B., et al.
Publicado: (2022)

Endothelial effects of antihypertensive treatment: focus on irbesartan
por: Negro, Roberto
Publicado: (2008)

Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension
por: Bramlage, Peter
Publicado: (2009)

Biochemical effects of irbesartan in experimental diabetic nephropathy
por: Vaishya, Richa, et al.
Publicado: (2009)

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cancer risk: an updated meta-analysis of observational studies
por: Shin, Kayeong, et al.
Publicado: (2022)

Angiotensin receptor blockers and COVID-19
por: Saavedra, Juan M.
Publicado: (2020)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020)

HaploBlocker: Creation of Subgroup-Specific Haplotype Blocks and Libraries
por: Pook, Torsten, et al.
Publicado: (2019)

Genetic variants of adiponectin receptor 2 are associated with increased adiponectin levels and decreased triglyceride/VLDL levels in patients with metabolic syndrome
por: Broedl, Uli C, et al.
Publicado: (2006)

Differential effects of fenofibrate versus atorvastatin on the concentrations of E-selectin and vascular cellular adhesion molecule-1 in patients with type 2 diabetes mellitus and mixed hyperlipoproteinemia: a randomized cross-over trial
por: Empen, Klaus, et al.
Publicado: (2003)

Renin-angiotensin system blockers regulate the metabolism of isolated fat cells in vitro
por: Caminhotto, R de O., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2imsma8i1kk07q5em3g6th2epn